In a mouse model of myocardial ischemia, CXCL12 treatment leads to increased levels of vascular endothelial growth factor (VEGF) and enhanced neo-angiogenesis, associated with reduced infarction size after myocardial infarction (98). This evidence concerns the gene VEGFA and infarction.